P's interim analysis is pushed back to Q3. I think
Post# of 72440
(Total Views: 287)
Posted On: 04/20/2017 7:47:51 PM
P's interim analysis is pushed back to Q3. I think that's part of the reasons for the sell-off today. My guess is the competition for patients are fierce from other psoriasis drugs, so Leo increased three more sites last month.
Quote:
I'm looking for the interim data for prurisol, supposed to be released 2nd quarter.
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼